Evaluating the clinical outcomes associated with insulin aspart versus human insulin as the bolus component of a basal bolus regimen for type 2 diabetes over patient lifetimes

Aim: To evaluate the long-term clinical implications of using insulin aspart (NovoRapid®) versus human insulin (HI) as the bolus component of basal-bolus therapy in type 2 diabetes patients in Germany. Material and Methods: A publishedcomputer simulation model of diabetes, previously validated against real-lifedata, was used to project long-term clinical outcomes. Three-month data forpatients in the German cohort (n=920) receiving insulin aspart or HI, both incombination with insulin detemir, from the PREDICTIVE observational study wasused as the basis of the analysis (mean age 63 years, duration of diabetes 13y…